Skip to Content
DiagnosticsDiagnostics
  • Article
  • Open Access

18 November 2026

12 Pages

Comparison of Actin FSL and Pathromtin SL aPTT Reagents in Patients Receiving Efanesoctocog Alfa: A Retrospective Laboratory Study

,
,
,
,
,
,
and
1
Institute of Laboratory Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany
2
Pediatric Thrombosis and Haemostasis Unit, Dr. von Hauner Children’s Hospital, LMU University Hospital, LMU Munich, 80337 Munich, Germany
3
Independent Researcher, 35043 Marburg, Germany
*
Author to whom correspondence should be addressed.
This article belongs to the Section Clinical Laboratory Medicine

Abstract

Background: Efanesoctocog alfa (EFA) is an extended half-life factor VIII (FVIII) concentrate. Although FVIII assay variability in EFA monitoring is established, data on the comparability of activated partial thromboplastin time (aPTT) reagents remain limited. This study compared Actin FSL and Pathromtin SL in post-infusion EFA samples, assessed lot-to-lot variability, and evaluated aPTT performance in detecting reduced FVIII activity. Methods: This retrospective, single-center study analyzed 106 paired samples from 53 patients receiving once-weekly EFA at trough level, peak level (1 h post-infusion), or follow-up (median 4.0 days). FVIII activity was measured using an Actin FSL-based one-stage clotting assay with FVIII-deficient plasma. aPTT was determined using Actin FSL and Pathromtin SL on Sysmex coagulation analyzers. Method comparison included Passing–Bablok regression and modified Bland–Altman analysis. Results: Pathromtin SL produced longer clotting times (mean bias: 5.2 s, mean relative difference: 13.1%). Both aPTT reagents showed a strong correlation in post-infusion EFA samples (Pearson’s r = 0.878). No significant differences in regression slopes were observed across reagent lot combinations; maximum relative inter-lot difference was 6.5%. Using assay-specific cut-offs, both aPTT assays showed 100% sensitivity for detecting FVIII activity < 30% in this cohort. Nevertheless, prolonged aPTT values also occurred at FVIII activity ≥ 30%, indicating limited specificity. Conclusions: Both Actin FSL and Pathromtin SL aPTT assays identified all samples with Actin FSL-based FVIII activity < 30%. However, significantly longer clotting times with Pathromtin SL necessitate assay-specific interpretation in clinical practice. Findings should be interpreted considering the limited sample size, retrospective single-center design and potential methodological dependency.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.